Indocap Capsule contains Indomethacin 25 mg, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of pain and inflammation associated with various musculoskeletal disorders, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and gouty arthritis. Indomethacin exerts its therapeutic effects by inhibiting the cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever. This mechanism results in effective alleviation of symptoms such as joint pain, swelling, and stiffness. Indocap Capsule is typically administered orally, with dosage individualized based on the severity of the condition and patient response. It is contraindicated in patients with known hypersensitivity to indomethacin or other NSAIDs, active peptic ulcer disease, severe renal or hepatic impairment, and in those with a history of asthma induced by NSAIDs. Caution is advised in elderly patients and those with cardiovascular risk factors, as NSAIDs may increase the risk of thrombotic events. Common adverse effects include gastrointestinal disturbances such as nausea, dyspepsia, and abdominal pain. Patients should be monitored regularly for signs of gastrointestinal bleeding and renal function during prolonged therapy. Indocap Capsule should be used under medical supervision to ensure optimal efficacy and safety.